{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:35:58Z","timestamp":1753889758282,"version":"3.41.2"},"reference-count":16,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Sci. OA"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.2144\/fsoa-2019-0079","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T14:19:22Z","timestamp":1576160362000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic Factors for Patients Treated With Abiraterone"],"prefix":"10.1080","volume":"6","author":[{"given":"Cec\u00edlia M","family":"Alvim","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"}]},{"given":"Andr\u00e9","family":"Mansinho","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"},{"name":"Lu\u00eds Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, 1649-028, Portugal"}]},{"given":"Rita S","family":"Paiva","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"}]},{"given":"Raquel","family":"Br\u00e1s","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"}]},{"given":"Patr\u00edcia M","family":"Semedo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"}]},{"given":"Soraia","family":"Lobo-Martins","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"}]},{"given":"Carolina B","family":"da Ponte","sequence":"additional","affiliation":[{"name":"Urology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"}]},{"given":"Daniela","family":"Macedo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"}]},{"given":"Leonor","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"}]},{"given":"Jos\u00e9 P","family":"dos Reis","sequence":"additional","affiliation":[{"name":"Urology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"}]},{"given":"Isabel","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"},{"name":"Lu\u00eds Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, 1649-028, Portugal"}]},{"given":"Lu\u00eds","family":"Costa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, 1649-035, Portugal"},{"name":"Lu\u00eds Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, 1649-028, Portugal"}]}],"member":"301","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_3_5_2_1","DOI":"10.3322\/caac.21254"},{"doi-asserted-by":"publisher","key":"e_1_3_5_3_1","DOI":"10.1056\/NEJMra1701695"},{"doi-asserted-by":"publisher","key":"e_1_3_5_4_1","DOI":"10.1056\/NEJMoa1209096"},{"doi-asserted-by":"publisher","key":"e_1_3_5_5_1","DOI":"10.1056\/NEJMoa1405095"},{"doi-asserted-by":"publisher","key":"e_1_3_5_6_1","DOI":"10.1016\/S1470-2045(12)70379-0"},{"doi-asserted-by":"publisher","key":"e_1_3_5_7_1","DOI":"10.1016\/j.clgc.2017.04.003"},{"issue":"5","key":"e_1_3_5_8_1","first-page":"6806","article-title":"Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer","volume":"15","author":"Hiroshige T","year":"2018","unstructured":"HiroshigeT , EguchiY , YoshizumiOet al.Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. Oncol. Lett.15(5), 6806\u20136814 (2018).","journal-title":"Oncol. Lett."},{"doi-asserted-by":"publisher","key":"e_1_3_5_9_1","DOI":"10.1016\/j.ejca.2016.03.070"},{"doi-asserted-by":"publisher","key":"e_1_3_5_10_1","DOI":"10.3390\/ijms17091520"},{"doi-asserted-by":"publisher","key":"e_1_3_5_11_1","DOI":"10.3389\/fphar.2016.00123"},{"doi-asserted-by":"publisher","key":"e_1_3_5_12_1","DOI":"10.1200\/JCO.2013.50.3201"},{"doi-asserted-by":"publisher","key":"e_1_3_5_13_1","DOI":"10.1016\/j.urolonc.2012.10.001"},{"doi-asserted-by":"publisher","key":"e_1_3_5_14_1","DOI":"10.21037\/tau.2018.05.10"},{"doi-asserted-by":"publisher","key":"e_1_3_5_15_1","DOI":"10.18632\/oncotarget.9485"},{"doi-asserted-by":"publisher","key":"e_1_3_5_16_1","DOI":"10.1016\/j.eururo.2016.02.055"},{"issue":"2","key":"e_1_3_5_17_1","first-page":"1057","article-title":"Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer","volume":"35","author":"Afshar M","year":"2015","unstructured":"AfsharM , Al-AllooshF , PirrieS , RowanC , JamesND , PorfiriEL. Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer. Anticancer Res.35(2), 1057\u20131063 (2015).","journal-title":"Anticancer Res."}],"container-title":["Future Science OA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2144\/fsoa-2019-0079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:49:09Z","timestamp":1719125349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2144\/fsoa-2019-0079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.2144\/fsoa-2019-0079"],"URL":"https:\/\/doi.org\/10.2144\/fsoa-2019-0079","relation":{},"ISSN":["2056-5623"],"issn-type":[{"type":"electronic","value":"2056-5623"}],"subject":[],"published":{"date-parts":[[2019,12,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifso20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifso20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"FSO436"}}